Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Constellation Brands has gained 11.6% over the past week to $126.40, yet short sellers keep adding. The gap between price action and positioning is wider now than at any point in recent weeks, and retail attention has spiked sharply alongside it.
Short interest stands at 5.5% of the free float as of October 12, up 11.5% on the week and 33.7% over the past month. That is a steady, deliberate accumulation, not a reaction to a single day. The previous convergence report noted the same pattern at $122.64. The stock has moved another 3% higher since then. Shorts have not covered.
The lending market does nothing to explain the build as a mechanically driven event. Availability sits at 3,956%, meaning there are roughly 40 shares available to borrow for every one already lent out. Cost to borrow dropped 62% over the past week to 0.14%, the lowest reading since September. Borrowing STZ has never been cheaper or easier. The short position is being added by choice, not forced by a tight borrow.
ORTEX Alt Data shows retail attention running 3.2 standard deviations above its own 90-day average, based on English Wikipedia article views and distinct visitors to the STZ ORTEX stock page. That is a sharp spike. Attention readings of this magnitude tend to accompany moments of genuine market debate rather than quiet drift.
The debate here is real. Since the October 7 earnings print, JP Morgan raised its target slightly to $136 from $133 while keeping its Neutral rating. That is the one constructive revision. Every other move since earnings has been a cut. Piper Sandler's Michael Lavery took the sharpest knife, dropping to $125 from $161 on a Neutral. The consensus mean target is $151.74. The stock at $126.40 implies roughly 20% to that figure, but targets have been moving toward the stock, not the other way around.
Freedom Broker stands apart. The firm upgraded to Buy while cutting its target to $158 from $173. That is the only rating upgrade in the recent wave, and it lands against a backdrop of near-universal target reductions from larger houses.
ORTEX forecasts a 47% probability that STZ joins the CRSP US Small index at the December 2026 Quarterly Review. The stock is currently 1.2% above the entry line, with the price that decides it at $124.90. At $126.40, STZ is already through that level. The rank date is December 4, announcement December 7, with trading on December 22. If the addition is confirmed, index trackers would need to buy an estimated $316 million, around 1.1 days of normal volume. The same review could also reduce STZ's weight in the CRSP US Large and CRSP US Mid indices, generating an estimated $251 million of combined selling. These are ORTEX forecasts, not announcements.
What to watch: whether the price holds above $124.90 through early December, and whether short interest continues to build or shows the first signs of covering as the stock pushes further from the bear thesis entry points.
See the live data behind this article on ORTEX.
Open STZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
